David M. Tanen, Director at Nile Therapeutics, Inc. (NLTX), bought 4,000 shares at $0.69 ($3K) on 2008-12-11, disclosed to the SEC on 2008-12-12.
Open-market purchase of $3k NLTX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| NLTX | BUY | 2008-12-15 | $9K | — | Filing → |